Lending a helping hand, screening chemical libraries for compounds that enhance β-hexosaminidase A activity in GM2 gangliosidosis cells

被引:47
作者
Tropak, Michael B.
Mahuran, Don
机构
[1] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
active-site-specific chaperones; enzyme enhancement therapy; hexosaminidase; high throughput screening; lysosomal; pharmacological chaperones; post translational regulation; Sandhoff; subunit assembly; Tay-Sachs;
D O I
10.1111/j.1742-4658.2007.06040.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Enzyme enhancement therapy is an emerging therapeutic approach that has the potential to treat many genetic diseases. Candidate diseases are those associated with a mutant protein that has difficulty folding and/or assembling into active oligomers in the endoplasmic reticulum. Many lysosomal storage diseases are candidates for enzyme enhancement therapy and have the additional advantage of requiring only 5-10% of normal enzyme levels to reduce and/or prevent substrate accumulation. Our long experience in working with the beta-hexosaminidase (EC 3.2.1.52) isozymes system and its associated deficiencies (Tay-Sachs and Sandhoff disease) lead us to search for possible enzyme enhancement therapy-agents that could treat the chronic forms of these diseases which express 2-5% residual activity. Pharmacological chaperones are enzyme enhancement therapy-agents that are competitive inhibitors of the target enzyme. Each of the known beta-hexosaminidase inhibitors ( low mu N IC50) increased mutant enzyme levels to >= 10% in chronic Tay-Sachs fibroblasts and also attenuated the thermo-denaturation of b-hexosaminidase. To expand the repertoire of pharmacological chaperones to more 'drug-like' compounds, we screened the Maybridge library of 50 000 compounds using a real-time assay for non-carbohydrate-based beta-hexosaminidase inhibitors and identified several that functioned as pharmacological chaperones in patient cells. Two of these inhibitors had derivatives that had been tested in humans for other purposes. These observations lead us to screen the NINDS library of 1040 Food and Drug Administration approved compounds for pharmacological chaperones. Pyrimethamine, an antimalarial drug with well documented pharmacokinetics, was confirmed as a beta-hexosaminidase pharmacological chaperone and compared favorably with our best carbohydrate-based pharmacological chaperone in patient cells with various mutant genotypes.
引用
收藏
页码:4951 / 4961
页数:11
相关论文
共 47 条
  • [1] Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells
    Aguado, C
    Pérez, B
    Ugarte, M
    Desviat, LR
    [J]. FEBS LETTERS, 2006, 580 (07) : 1697 - 1701
  • [2] ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765
  • [3] Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs
    Arakawa, Tsutomu
    Ejima, Daisuke
    Kita, Yoshiko
    Tsumoto, Kouhei
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2006, 1764 (11): : 1677 - 1687
  • [4] Multiplex analysis of inflammatory signaling pathways using a high-content imaging system
    Bertelsen, Malene
    [J]. MEASURING BIOLOGICAL RESPONSES WITH AUTOMATED MICROSCOPY, 2006, 414 : 348 - 363
  • [5] BROWN CA, 1993, AM J HUM GENET, V53, P497
  • [6] Buxton I.L. O., 2006, Goodman Gilman's The Pharmacological Basis of Therapeutics, V11
  • [7] Protein folding as posttranslational regulation: Evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor
    Conn, P. Michael
    Knollman, Paul E.
    Brothers, Shaun P.
    Janovick, Jo Ann
    [J]. MOLECULAR ENDOCRINOLOGY, 2006, 20 (12) : 3035 - 3041
  • [8] Nicotine enhances intracellular nicotinic receptor maturation: A novel mechanism of neural plasticity?
    Corringer, PJ
    Sallette, J
    Changeux, JP
    [J]. JOURNAL OF PHYSIOLOGY-PARIS, 2006, 99 (2-3) : 162 - 171
  • [9] DAZZO A, 1984, J BIOL CHEM, V259, P1070
  • [10] Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders
    Desnick, RJ
    Schuchman, EH
    [J]. NATURE REVIEWS GENETICS, 2002, 3 (12) : 954 - 966